An update on the development of drugs for neuropsychiatric disorders: focusing on the σ1receptor ligand
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The sigma1 receptor is an intracellular molecule that shares no homology with any mammalian proteins. sigma1 receptors normally localize at the endoplasmic reticulum and regulate a variety of signal transductions including intracellular Ca2+ dynamics and neurotrophic factor signaling. In the brain, sigma1 receptors are known to regulate the activity of diverse ion channels via protein-protein interactions. Accumulated evidences strongly indicate that the activation/upregulation of sigma1 receptors promotes the neuronal differentiation as well as a robust antiapoptotic action. In animals, sigma1 receptor agonists exhibit an antidepressant-like action. Furthermore, the agonists enhanced neuronal survival eventhough they were administered several hours after a brain ischemia. Thus, primary clinical targets of sigma1 receptor ligands are proposed to include stroke, neurodegenerative disorders and depression. Ligands for the sigma1 receptor may constitute a new class of therapeutic drugs targeting an endoplasmic reticular protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Hayashi, T., & Su, T.-P. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051284 · Cited by 262
Self-citationInteractions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain
Narita, N., Hashimoto, K., Tomitaka, S.-I., & Minabe, Y. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00254-3 · Cited by 254 · cited 2×
“1996; 307 :117-19 [67] , with permission from Elsevier.”
BackgroundYagasaki, Y., Numakawa, T., Kumamaru, E., Hayashi, T., Su, T.-P., & Kunugi, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508157200 · Cited by 122 · cited 2×
“, NGF, epidermal growth factor and BDNF receptors, phosphorylation of extracellular signal-regulated kinase) [63-65] .”
BackgroundSelf-citation
Cited by
Pal, A., Fontanilla, D., Gopalakrishnan, A., Chae, Y.-K., Markley, J. L., & Ruoho, A. E. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.01.030 · Cited by 177
“…2008) haloperidol, BD 1047, and BD 1063 further increased the oxidative stress levels in sigma-1 receptor transfected COS-7 cells compared to control (no drug treatment) whereas (+)-pentazocine, a sigma-1 receptor agonist (Hayashi and Su, 2008), showed a decrease in oxidative stress levels (Fig 4).”
BackgroundInfluentialDextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141
Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089985 · Cited by 99
“Compared to existing medications, s1 receptor agonists may facilitate a more rapid onset of antidepressant efficacy [23].”
BackgroundInvolvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice
Nguyen, L., & Matsumoto, R. R. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.024 · Cited by 51
Zhang, C.-L., Feng, Z.-J., Liu, Y., Ji, X.-H., Peng, J.-Y., Zhang, X.-H., Zhen, X.-C., & Li, B.-M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051910 · Cited by 41
“improve cognitive impairment and neuropsychiatric diseases symptoms like depression, stress, anxiety and senile dementia [42,96,103].”
Background
Metadata
- Authors
- Hayashi, T., & Su, T.-P.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2007-12-13
- Volume
- 12
- Issue
- 1
- Pages
- 45-58
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2118955023
- Cited by
- 91
- References
- 4
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An update on the development of drugs for neuropsychiatric disorders: focusing on the σ1receptor ligand. https://app.cochat.ai/papers/10.1517/14728222.12.1.45
- The paper
- Hayashi, T., & Su, T.-P. (2008). An update on the development of drugs for neuropsychiatric disorders: focusing on the σ1receptor ligand. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.12.1.45
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.